Amniotic Membrane Market - By Product, By Application, By End Use – Global Forecast, 2024 – 2032

Amniotic Membrane Market Size

The global amniotic membrane market size was valued at around USD 1.7 billion in 2023 and is estimated to grow at a 7.9% CAGR from 2024 to 2032. The amniotic membrane is a thin, flexible tissue that lines the amniotic sac during pregnancy. It surrounds and protects the developing fetus while providing essential nutrients and growth factors. After childbirth, it can be used in medical treatments and surgeries for its regenerative properties and ability to promote healing.
 

Growing demand for regenerative medicine is anticipated to drive market growth. Regenerative medicine aims to restore or replace damaged tissues and organs using techniques such as stem cell therapy, tissue engineering, and biomaterials. Amniotic membranes are increasingly recognized for their potential in these applications due to their unique properties. A 2023 study published by the National Library of Medicine highlighted the presence of key bioactive molecules in the amniotic membrane, underscoring their regenerative properties.
 

Additionally, the rising incidence of chronic wounds, advancements in biotechnology and tissue engineering, and increasing awareness and acceptance of amniotic membrane products also support revenue growth in the market. Educational initiatives, including medical conferences and training programs, are promoting an understanding among clinicians. Simultaneously, patient awareness and demand for advanced therapies have increased with greater access to medical information and advocacy efforts.
 

Amniotic Membrane Market Trends

The market is experiencing significant growth, driven by its wide-ranging applications in healthcare, especially in wound care, ophthalmology, and regenerative medicine.
 

• The adoption of amniotic membrane transplantation to address ocular surface disorders, including corneal ulcers, chemical burns, and conjunctival defects, is increasing in ophthalmic surgeries. The rising popularity of cryopreserved amniotic membranes for corneal repair and regeneration stems from their efficacy in promoting healing and minimizing scarring in corneal epithelial defects and other surface disorders.
   
• There's growing demand for amniotic membrane products in treating chronic wounds such as diabetic foot ulcers and pressure ulcers and venous leg ulcers. Additionally, due to their healing-promoting properties and pain-reducing effects, amniotic membranes are increasingly used in burn care.
   
• Recent advancements in cryopreservation techniques have not only enhanced the efficacy and shelf-life of amniotic membrane products but also ensured the retention of their biological properties, amplifying their medical effectiveness.
   
• The introduction of dehydrated amniotic membrane products has further invigorated the market, given their extended shelf life, ease of storage and transport, and comparable therapeutic benefits to their cryopreserved counterparts.
   

Amniotic Membrane Market Analysis

Based on product, the market is divided into cryopreserved and lyophilized. The cryopreserved segment of the market is forecasted to reach USD 1.7 billion by 2032.
 

• Cryopreserved amniotic membrane (CAM) is extensively utilized across various medical disciplines due to its unique properties. In ophthalmology, it is employed to treat corneal defects, such as persistent epithelial defects, ulcers, and chemical burns, thereby promoting faster healing and reducing inflammation and scarring.
   
• In wound care, CAM has become an effective product for managing chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure sores. It provides a biological scaffold that supports cell proliferation and tissue regeneration. Additionally, its anti-inflammatory and antimicrobial properties help reduce infection risks and create a conducive healing environment, supporting its preference and revenue growth in the market.
   

Based on application, the amniotic membrane market is bifurcated into surgical wounds, ophthalmology, stem cell biology, regenerative medicine, prenatal diagnosis, orthopedics, dermatology, plastic surgery, dentistry, and gynecology. The ophthalmology segment dominated the market with a revenue of USD 342.1 million in 2023.
 

• Amniotic membrane transplantation (AMT) is utilized in ophthalmology to address various ocular surface disorders. The amniotic membrane, the innermost layer of the placenta, offers several beneficial properties, including providing a substrate for epithelial cell growth due to its collagen composition, reducing inflammation, preventing new blood vessel formation, and offering analgesic effects by covering nerve endings.
   
• The growing prevalence of ocular surface disorders, including corneal ulcers, pterygium, and dry eye diseases, driven by factors such as aging populations and increased incidence of ocular trauma, is fueling demand for advanced treatment options. Additionally, advancements in surgical techniques and a better understanding of the benefits of amniotic membranes are expanding its applications and increasing its adoption.
   
• Furthermore, enhanced availability and improved processing methods contribute to its growing use in ophthalmic procedures, making the membrane more accessible and easier to apply.
   

Based on end-use, the amniotic membrane market is bifurcated into hospitals, ambulatory surgical centers (ASCs), specialty clinics, research and academic institutes, and other end-users. The hospitals segment held a market share of 40.7% in 2023 and is estimated to grow significantly.
 

• Hospitals benefit from the regenerative properties, anti-inflammatory effects, and scar-reducing capabilities of amniotic membranes, making them particularly valuable for treating chronic wounds, corneal defects, and during reconstructive surgeries.
   
• They are especially effective in treating chronic wounds, burns, and post-surgical sites due to their anti-inflammatory, antifibrotic, and antimicrobial properties, which promote faster healing and reduce the risk of infection.
   
• Increasing demand in hospital settings is driven by the need for advanced and effective treatment options to enhance patient outcomes, underscoring the significant role of amniotic membranes in contemporary medical care.
   

The growth of the amniotic membrane market in the U.S. is projected to reach USD 1.1 billion by 2032.
 

• Key factors driving this growth include the presence of well-established healthcare facilities and leading industry players in the country. The increasing emphasis on regenerative medicine and the rapid adoption of advanced technologies also contribute to market expansion.
   
• Additionally, the rising incidence of accidents, including road traffic collisions and trauma events, is anticipated to drive market growth. For example, as of March 2023, approximately 7.3 million motor vehicle accidents occur annually in the U.S.
   
• Furthermore, favorable regulatory frameworks and ongoing investment in research and development are expected to support a positive market outlook during the forecast period.
   

The amniotic membrane market in the UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The country’s well-established public healthcare system and the widespread implementation of universal healthcare contribute to the growing demand for advanced medical treatments, including amniotic membranes.
   
• Additionally, the rising prevalence of chronic diseases such as cardiovascular conditions, cancer, and diabetes is driving the need for effective regenerative therapies that support wound healing and tissue repair in the UK, further boosting market growth.
   

The amniotic membrane market in Japan is anticipated to witness lucrative growth between 2024 and 2032.
 

• The availability of trained professionals and the development of healthcare facilities are expected to drive market growth in Japan during the forecast period. Rising awareness of the benefits provided by amniotic membranes is also expected to further propel market expansion.
   
• Moreover, Japan's growing healthcare expenditure, which accounted for 9.8% of its GDP in 2022 according to the Organization for Economic Cooperation and Development (OECD), is projected to stimulate revenue growth in the market during the forecast period.
   

The amniotic membrane market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• This market growth is driven by several key factors, including high spending capacity and living standards, well-established medical infrastructure, and a rising incidence of cancer.
   
• Additionally, increasing government initiatives aimed at expanding reimbursement coverage are expected to enhance market penetration during the forecast period. The projected rise in healthcare spending in Saudi Arabia, estimated at USD 50.4 billion for 2023, according to a report by the International Trade Administration and the U.S. Department of Commerce, is expected to further support market expansion.
   

Amniotic Membrane Market Share

The market is competitive, with a mix of major global and smaller to medium-sized companies vying for market share. Prominent players in the market include MiMedx Group, Inc., Smith & Nephew plc, Integra LifeSciences Holdings Corporation, and Organogenesis Holdings Inc. These leading companies employ various strategies to maintain competitive advantages, including strategic collaborations, partnerships, and mergers, allowing them to capture the highest market share and outperform the competition.
 

Amniotic Membrane Market Companies

Some of the eminent market participants operating in the amniotic membrane industry include:

• Amnio Technology, LLC
• Applied Biologics LLC
• BioTissue Holdings Inc.
• Celularity Inc.
• Corza Health, Inc.
• Integra LifeSciences Holdings Corporation
• MiMedx Group, Inc.
• Organogenesis Holdings Inc.
• Skye Biologics, Inc.
• Smith & Nephew plc
   

Amniotic Membrane Industry News:

• In September 2023, MiMedx Group, Inc. announced the launch of EPIEFFECT, the latest addition to its portfolio of advanced wound care (AWC) solutions. The product features a thick, tri-layer configuration, making it suitable for securing the graft in place with sutures. Its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds.
   
• In January 2023, MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that it had entered into an exclusive distribution agreement with Gunze Medical Limited, a subsidiary of Gunze Limited, for the sale of EPIFIX in Japan. MiMedx received regulatory approval for EPIFIX from the Japanese Ministry of Health, Labour and Welfare in June 2021, with reimbursement approval at a rate of JPY 35,100/cm² in September 2022. This partnership provided MiMedx with a strategic advantage, expanding its market presence in Japan and increasing access to its innovative wound care solutions in the region.
   

The amniotic membrane market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Cryopreserved
• Lyophilized   

Market, By Application

• Surgical wounds
• Ophthalmology
• Stem cell biology
• Regenerative medicine
• Prenatal diagnosis
• Orthopedics
• Dermatology
• Plastic surgery
• Dentistry
• Gynecology

Market, By End Use

• Hospitals
• Ambulatory surgical centers (ASCs)
• Specialty clinics
• Research and academic institutes
• Other end-users                                                                

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa